ArticleInvestigational new drugs2023

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Anastasios Stathis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.